-
Something wrong with this record ?
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial
D. Lorusso, Y. Xiang, K. Hasegawa, G. Scambia, M. Leiva, P. Ramos-Elias, A. Acevedo, J. Cvek, L. Randall, AJ. Pereira de Santana Gomes, F. Contreras Mejía, L. Helpman, H. Akıllı, JY. Lee, V. Saevets, F. Zagouri, L. Gilbert, J. Sehouli, E....
Language English Country England, Great Britain
Document type Journal Article, Randomized Controlled Trial, Clinical Trial, Phase III, Multicenter Study
NLK
ProQuest Central
from 1992-01-04 to 3 months ago
Nursing & Allied Health Database (ProQuest)
from 1992-01-04 to 3 months ago
Health & Medicine (ProQuest)
from 1992-01-04 to 3 months ago
Family Health Database (ProQuest)
from 1992-01-04 to 3 months ago
Psychology Database (ProQuest)
from 1992-01-04 to 3 months ago
Health Management Database (ProQuest)
from 1992-01-04 to 3 months ago
Public Health Database (ProQuest)
from 1992-01-04 to 3 months ago
- MeSH
- Adenocarcinoma drug therapy mortality radiotherapy MeSH
- Carcinoma, Adenosquamous drug therapy mortality radiotherapy MeSH
- Chemoradiotherapy * methods MeSH
- Progression-Free Survival MeSH
- Adult MeSH
- Double-Blind Method MeSH
- Antibodies, Monoclonal, Humanized * adverse effects therapeutic use MeSH
- Middle Aged MeSH
- Humans MeSH
- Uterine Cervical Neoplasms * drug therapy mortality radiotherapy MeSH
- Antineoplastic Agents, Immunological therapeutic use adverse effects MeSH
- Antineoplastic Combined Chemotherapy Protocols therapeutic use MeSH
- Aged MeSH
- Carcinoma, Squamous Cell drug therapy mortality radiotherapy MeSH
- Neoplasm Staging MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Clinical Trial, Phase III MeSH
- Multicenter Study MeSH
- Randomized Controlled Trial MeSH
BACKGROUND: At the first interim analysis of the phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study, the addition of pembrolizumab to chemoradiotherapy provided a statistically significant and clinically meaningful improvement in progression-free survival in patients with locally advanced cervical cancer. We report the overall survival results from the second interim analysis of this study. METHODS: Eligible patients with newly diagnosed, high-risk (FIGO 2014 stage IB2-IIB with node-positive disease or stage III-IVA regardless of nodal status), locally advanced, histologically confirmed, squamous cell carcinoma, adenocarcinoma, or adenosquamous cervical cancer were randomly assigned 1:1 to receive five cycles of pembrolizumab (200 mg) or placebo every 3 weeks with concurrent chemoradiotherapy, followed by 15 cycles of pembrolizumab (400 mg) or placebo every 6 weeks. Pembrolizumab or placebo and cisplatin were administered intravenously. Patients were stratified at randomisation by planned external beam radiotherapy type (intensity-modulated radiotherapy [IMRT] or volumetric-modulated arc therapy [VMAT] vs non-IMRT or non-VMAT), cervical cancer stage at screening (FIGO 2014 stage IB2-IIB node positive vs III-IVA), and planned total radiotherapy (external beam radiotherapy plus brachytherapy) dose (<70 Gy vs ≥70 Gy [equivalent dose of 2 Gy]). Primary endpoints were progression-free survival per RECIST 1.1 by investigator or by histopathological confirmation of suspected disease progression and overall survival defined as the time from randomisation to death due to any cause. Safety was a secondary endpoint. FINDINGS: Between June 9, 2020, and Dec 15, 2022, 1060 patients at 176 sites in 30 countries across Asia, Australia, Europe, North America, and South America were randomly assigned to treatment, with 529 patients in the pembrolizumab-chemoradiotherapy group and 531 patients in the placebo-chemoradiotherapy group. At the protocol-specified second interim analysis (data cutoff Jan 8, 2024), median follow-up was 29·9 months (IQR 23·3-34·3). Median overall survival was not reached in either group; 36-month overall survival was 82·6% (95% CI 78·4-86·1) in the pembrolizumab-chemoradiotherapy group and 74·8% (70·1-78·8) in the placebo-chemoradiotherapy group. The hazard ratio for death was 0·67 (95% CI 0·50-0·90; p=0·0040), meeting the protocol-specified primary objective. 413 (78%) of 528 patients in the pembrolizumab-chemoradiotherapy group and 371 (70%) of 530 in the placebo-chemoradiotherapy group had a grade 3 or higher adverse event, with anaemia, white blood cell count decreased, and neutrophil count decreased being the most common adverse events. Potentially immune-mediated adverse events occurred in 206 (39%) of 528 patients in the pembrolizumab-chemoradiotherapy group and 90 (17%) of 530 patients in the placebo-chemoradiotherapy group. This study is registered with ClinicalTrials.gov, NCT04221945. INTERPRETATION: Pembrolizumab plus chemoradiotherapy significantly improved overall survival in patients with locally advanced cervical cancer These data, together with results from the first interim analysis, support this immuno-chemoradiotherapy strategy as a new standard of care for this population. FUNDING: Merck Sharp & Dohme, a subsidiary of Merck & Co.
Clinical Therapeutics Alexandra Hospital Athens Greece
Department of Gynecology Charite Universitaetsmedizin Berlin Germany
Department of Obstetrics and Gynecology Ehime University Hospital Toon Ehime Japan
Department of Obstetrics and Gynecology MacKay Memorial Hospital Taipei Taiwan
Department of Obstetrics and Gynecology Medical University of Graz Graz Austria
Department of Oncology University of Ostrava North Moravia Czech Republic
Department of Oncology Xiangya Hospital Central South University Hunan China
Department of Radiation Oncology University Hospitals Leuven Leuven Belgium
Gynaecology Oncology Unit Fondazione Policlinico Universitario A Gemelli IRCCS Rome Italy
Gynaecology Oncology Unit Humanitas San Pio 10 Milan Italy
Gynelogic Oncology University of Virginia School of Medicine Charlottesville VA USA
Meir Medical Center Sackler School of Medicine Tel Aviv University Kfar Saba Israel
North Eastern German Society of Gynecological Oncology Berlin Germany
Oncología Clínica Instituto Nacional de Cancerologia Bogota Colombia
Oncologia Clínica Liga Norte Riograndense Contra o Cancer Natal Rio Grande do Norte Brazil
Oncología Médica Instituto Peruano de Oncología y Radioterapia Lima Perú
Oncología Médica Integra Cancer Institute Edificio Integra Medical Center Guatemala City Guatemala
Turkish Society of Gynecologic Oncology Başkent University Ankara Turkiye
Yonsei Cancer Center and Severance Hospital Yonsei University College of Medicine Seoul South Korea
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25003933
- 003
- CZ-PrNML
- 005
- 20250206104812.0
- 007
- ta
- 008
- 250121s2024 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/S0140-6736(24)01808-7 $2 doi
- 035 __
- $a (PubMed)39288779
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Lorusso, Domenica $u Gynaecology Oncology Unit, Fondazione Policlinico Universitario A Gemelli IRCCS, Rome, Italy; Gynaecology Oncology Unit, Humanitas San Pio X, Milan, Italy. Electronic address: domenica.lorusso@hunimed.eu
- 245 10
- $a Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial / $c D. Lorusso, Y. Xiang, K. Hasegawa, G. Scambia, M. Leiva, P. Ramos-Elias, A. Acevedo, J. Cvek, L. Randall, AJ. Pereira de Santana Gomes, F. Contreras Mejía, L. Helpman, H. Akıllı, JY. Lee, V. Saevets, F. Zagouri, L. Gilbert, J. Sehouli, E. Tharavichitkul, K. Lindemann, N. Colombo, CL. Chang, M. Bednarikova, H. Zhu, A. Oaknin, M. Christiaens, E. Petru, T. Usami, P. Liu, K. Yamada, S. Toker, SM. Keefe, S. Pignata, LR. Duska, ENGOT-cx11/GOG-3047/KEYNOTE-A18 investigators
- 520 9_
- $a BACKGROUND: At the first interim analysis of the phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study, the addition of pembrolizumab to chemoradiotherapy provided a statistically significant and clinically meaningful improvement in progression-free survival in patients with locally advanced cervical cancer. We report the overall survival results from the second interim analysis of this study. METHODS: Eligible patients with newly diagnosed, high-risk (FIGO 2014 stage IB2-IIB with node-positive disease or stage III-IVA regardless of nodal status), locally advanced, histologically confirmed, squamous cell carcinoma, adenocarcinoma, or adenosquamous cervical cancer were randomly assigned 1:1 to receive five cycles of pembrolizumab (200 mg) or placebo every 3 weeks with concurrent chemoradiotherapy, followed by 15 cycles of pembrolizumab (400 mg) or placebo every 6 weeks. Pembrolizumab or placebo and cisplatin were administered intravenously. Patients were stratified at randomisation by planned external beam radiotherapy type (intensity-modulated radiotherapy [IMRT] or volumetric-modulated arc therapy [VMAT] vs non-IMRT or non-VMAT), cervical cancer stage at screening (FIGO 2014 stage IB2-IIB node positive vs III-IVA), and planned total radiotherapy (external beam radiotherapy plus brachytherapy) dose (<70 Gy vs ≥70 Gy [equivalent dose of 2 Gy]). Primary endpoints were progression-free survival per RECIST 1.1 by investigator or by histopathological confirmation of suspected disease progression and overall survival defined as the time from randomisation to death due to any cause. Safety was a secondary endpoint. FINDINGS: Between June 9, 2020, and Dec 15, 2022, 1060 patients at 176 sites in 30 countries across Asia, Australia, Europe, North America, and South America were randomly assigned to treatment, with 529 patients in the pembrolizumab-chemoradiotherapy group and 531 patients in the placebo-chemoradiotherapy group. At the protocol-specified second interim analysis (data cutoff Jan 8, 2024), median follow-up was 29·9 months (IQR 23·3-34·3). Median overall survival was not reached in either group; 36-month overall survival was 82·6% (95% CI 78·4-86·1) in the pembrolizumab-chemoradiotherapy group and 74·8% (70·1-78·8) in the placebo-chemoradiotherapy group. The hazard ratio for death was 0·67 (95% CI 0·50-0·90; p=0·0040), meeting the protocol-specified primary objective. 413 (78%) of 528 patients in the pembrolizumab-chemoradiotherapy group and 371 (70%) of 530 in the placebo-chemoradiotherapy group had a grade 3 or higher adverse event, with anaemia, white blood cell count decreased, and neutrophil count decreased being the most common adverse events. Potentially immune-mediated adverse events occurred in 206 (39%) of 528 patients in the pembrolizumab-chemoradiotherapy group and 90 (17%) of 530 patients in the placebo-chemoradiotherapy group. This study is registered with ClinicalTrials.gov, NCT04221945. INTERPRETATION: Pembrolizumab plus chemoradiotherapy significantly improved overall survival in patients with locally advanced cervical cancer These data, together with results from the first interim analysis, support this immuno-chemoradiotherapy strategy as a new standard of care for this population. FUNDING: Merck Sharp & Dohme, a subsidiary of Merck & Co.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a adenokarcinom $x farmakoterapie $x mortalita $x radioterapie $7 D000230
- 650 12
- $a humanizované monoklonální protilátky $x škodlivé účinky $x terapeutické užití $7 D061067
- 650 _2
- $a protinádorové látky imunologicky aktivní $x terapeutické užití $x škodlivé účinky $7 D000074322
- 650 _2
- $a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
- 650 _2
- $a adenoskvamózní karcinom $x farmakoterapie $x mortalita $x radioterapie $7 D018196
- 650 _2
- $a spinocelulární karcinom $x farmakoterapie $x mortalita $x radioterapie $7 D002294
- 650 12
- $a chemoradioterapie $x metody $7 D059248
- 650 _2
- $a dvojitá slepá metoda $7 D004311
- 650 _2
- $a staging nádorů $7 D009367
- 650 _2
- $a doba přežití bez progrese choroby $7 D000077982
- 650 12
- $a nádory děložního čípku $x farmakoterapie $x mortalita $x radioterapie $7 D002583
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 655 _2
- $a klinické zkoušky, fáze III $7 D017428
- 655 _2
- $a multicentrická studie $7 D016448
- 700 1_
- $a Xiang, Yang $u Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, National Clinical Research Center for Obstetric & Gynecologic Diseases, Beijing, China
- 700 1_
- $a Hasegawa, Kosei $u Department of Obstetrics and Gynecology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan
- 700 1_
- $a Scambia, Giovanni $u Scientific Directorate, Fondazione Policlinico Universitario Agostino Gemelli IRCCS and Catholic University of the Sacred Heart, Rome, Italy
- 700 1_
- $a Leiva, Manuel $u Oncología Médica, Instituto Peruano de Oncología y Radioterapia, Lima, Perú
- 700 1_
- $a Ramos-Elias, Pier $u Oncología Médica, Integra Cancer Institute, Edificio Integra Medical Center, Guatemala City, Guatemala
- 700 1_
- $a Acevedo, Alejandro $u Oncocentro, Valparaiso, Chile
- 700 1_
- $a Cvek, Jakub $u Department of Oncology, University of Ostrava, North Moravia, Czech Republic
- 700 1_
- $a Randall, Leslie $u Gynecologic Oncology, Virginia Commonwealth University, Massey Comprehensive Cancer Center, Richmond, VA, USA
- 700 1_
- $a Pereira de Santana Gomes, Andrea Juliana $u Oncologia Clínica, Liga Norte Riograndense Contra o Cancer, Natal, Rio Grande do Norte, Brazil
- 700 1_
- $a Contreras Mejía, Fernando $u Oncología Clínica, Instituto Nacional de Cancerologia, Bogota, Colombia
- 700 1_
- $a Helpman, Limor $u Meir Medical Center, Sackler School of Medicine, Tel Aviv University, Kfar Saba, Israel
- 700 1_
- $a Akıllı, Hüseyin $u Turkish Society of Gynecologic Oncology, Başkent University, Ankara, Turkiye
- 700 1_
- $a Lee, Jung-Yun $u Yonsei Cancer Center and Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea
- 700 1_
- $a Saevets, Valeriya $u Gynaecological Oncology, Chelyabinsk Regional Clinical Center for Oncology and Nuclear Medicine, Chelyabinsk, Russia
- 700 1_
- $a Zagouri, Flora $u Clinical Therapeutics, Alexandra Hospital, Athens, Greece
- 700 1_
- $a Gilbert, Lucy $u Division of Gynecologic Oncology, McGill University Health Centre, Research Institute-McGill University Health Centre, Gerald Bronfman Department of Oncology McGill University, Montreal, QC, Canada
- 700 1_
- $a Sehouli, Jalid $u Department of Gynecology, Charite Universitaetsmedizin, Berlin, Germany; North-Eastern German Society of Gynecological Oncology, Berlin, Germany
- 700 1_
- $a Tharavichitkul, Ekkasit $u Division of Radiation Oncology, Department of Radiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
- 700 1_
- $a Lindemann, Kristina $u Department of Gynecological Oncology, Oslo University Hospital and the Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Nordic Society of Gynaecological Oncology Clinical Trial Unit, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
- 700 1_
- $a Colombo, Nicoletta $u Department of Obstetrics and Gynecology, University of Milan-Bicocca and European Institute of Oncology IRCCS, -Milan, Italy
- 700 1_
- $a Chang, Chih-Long $u Department of Obstetrics and Gynecology, MacKay Memorial Hospital, Taipei, Taiwan
- 700 1_
- $a Bednarikova, Marketa $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic
- 700 1_
- $a Zhu, Hong $u Department of Oncology, Xiangya Hospital, Central South University, Hunan, China
- 700 1_
- $a Oaknin, Ana $u Medical Oncology Service, Vall d'Hebron Institute of Oncology, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain
- 700 1_
- $a Christiaens, Melissa $u Department of Radiation Oncology, University Hospitals Leuven, Leuven, Belgium
- 700 1_
- $a Petru, Edgar $u Department of Obstetrics and Gynecology, Medical University of Graz, Graz, Austria; AGO-Austria, Innsbruck, Austria
- 700 1_
- $a Usami, Tomoka $u Department of Obstetrics and Gynecology, Ehime University Hospital, Toon, Ehime, Japan
- 700 1_
- $a Liu, Peng $u Merck & Co, Rahway, NJ, USA
- 700 1_
- $a Yamada, Karin $u Merck & Co, Rahway, NJ, USA
- 700 1_
- $a Toker, Sarper $u Merck & Co, Rahway, NJ, USA
- 700 1_
- $a Keefe, Stephen M $u Merck & Co, Rahway, NJ, USA
- 700 1_
- $a Pignata, Sandro $u Department of Urology and Gynecology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli, Italy
- 700 1_
- $a Duska, Linda R $u Gynelogic Oncology, University of Virginia School of Medicine, Charlottesville, VA, USA
- 710 2_
- $a ENGOT-cx11/GOG-3047/KEYNOTE-A18 investigators
- 773 0_
- $w MED00010161 $t Lancet $x 1474-547X $g Roč. 404, č. 10460 (2024), s. 1321-1332
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39288779 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250121 $b ABA008
- 991 __
- $a 20250206104807 $b ABA008
- 999 __
- $a ok $b bmc $g 2263589 $s 1239940
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 404 $c 10460 $d 1321-1332 $e 20240914 $i 1474-547X $m Lancet $n Lancet $x MED00010161
- LZP __
- $a Pubmed-20250121
